<DOC>
	<DOCNO>NCT02589717</DOCNO>
	<brief_summary>This open-label , multicenter , single-arm , expanded access program ( EAP ) design provide atezolizumab access participant locally advance metastatic urothelial carcinoma progress , intolerant , platinum-containing chemotherapy regimen .</brief_summary>
	<brief_title>An Expanded Access Study Atezolizumab Participants With Locally Advanced Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Able comply study protocol , investigator 's judgment Histologically cytologically document locally advanced metastatic urothelial carcinoma ( include renal pelvis , ureter , urinary bladder , urethra ) Disease progression follow treatment least one platinumcontaining regimen ( e.g. , gemcitabine cisplatin [ GC ] , methotrexate , vinblastine , doxorubicin , cisplatin [ MVAC ] , carboplatin gemcitabine [ CarboGem ] , etc . ) inoperable locally advanced metastatic urothelial carcinoma disease recurrence Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 , 2 Life expectancy &gt; /= 12 week Adequate hematologic endorgan function , define laboratory result obtain within 14 day prior first study treatment For woman postmenopausal ( &gt; /= 12 month nontherapyinduced amenorrhea ) surgically sterile ( absence ovary and/or uterus ) : agreement remain abstinent use single combine nonhormonal contraceptive method result failure rate &lt; 1 % per year treatment period least 90 day last dose study drug Treatment investigational agent participation another clinical trial therapeutic intent within 28 day prior enrollment Treatment chemotherapy 14 day prior enrollment ; however , participant may rescreened 14day washout period Treatment radiotherapy 7 day prior enrollment ; however , participant may rescreened 14day washout period Known primary central nervous system ( CNS ) malignancy symptomatic CNS metastasis Pregnant lactating , intend become pregnant study Significant cardiovascular disease , New York Heart Association cardiac disease ( Class II great ) , myocardial infarction within 3 month prior randomization , unstable arrhythmia , unstable angina Severe infection within 4 week prior enrollment , include , limited , hospitalization complication infection , bacteremia , severe pneumonia Received therapeutic oral intravenous ( IV ) antibiotic within 14 day prior enrollment ; however , participant may rescreened 14day washout period Major surgical procedure within 4 week prior enrollment anticipation need major surgical procedure course study diagnosis History severe allergic , anaphylactic , hypersensitivity reaction chimeric humanize antibody fusion protein Known hypersensitivity allergy biopharmaceuticals produce Chinese hamster ovary cell component atezolizumab formulation Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug render participant high risk treatment complication Participants active hepatitis B Active tuberculosis Administration live , attenuate vaccine within 4 week prior enrollment anticipation live , attenuated vaccine require study Treatment systemic immunostimulatory agent ( include , limited , interferon IL2 ) within 4 week five halflives drug , whichever short , prior enrollment Treatment systemic corticosteroid systemic immunosuppressive medication ( include , limited , prednisone , dexamethasone , cyclophosphamide , azathioprine , methotrexate , thalidomide , antitumor necrosis factor [ antiTNF ] agent ) within 2 week prior enrollment anticipate requirement systemic immunosuppressive medication trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>